| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01015040 | Bioavailability of Solifenacin Succinate|Pharmacokinetics of Solifenacin Succinate|Healthy Volunteers | Drug: solifenacin succinate suspension|Drug: solifenacin succinate tablet | Astellas Pharma Inc | Phase 1 | 2009-09-01 | 2009-12-04 |
| NCT01371994 | Urinary Incontinence | Drug: solifenacin succinate|Drug: Placebo | Astellas Pharma Inc | Phase 4 | 2011-08-01 | 2014-10-06 |
| NCT01539707 | Overactive Bladder|Neurogenic Detrusor Overactivity | Drug: Solifenacin succinate | Astellas Pharma Inc | Phase 1 | 2012-03-01 | 2012-10-29 |
| NCT00454740 | Urinary Bladder, Overactive | Drug: solifenacin succinate | Astellas Pharma Inc | Phase 3 | 2004-06-01 | 2014-09-17 |
| NCT00463541 | Urinary Bladder, Overactive | Drug: solifenacin succinate | Astellas Pharma Inc | Phase 3 | 2004-06-01 | 2014-09-17 |
| NCT00773552 | Urinary Urge|Urge Incontinence|Overactive Bladder | Drug: solifenacin succinate|Drug: placebo | Stamford Hospital | Phase 4 | 2008-11-01 | 2016-12-05 |
| NCT00985387 | Urinary Bladder, Overactive|Overactive Bladder | Drug: Solifenacin | Astellas Pharma Inc|Astellas Pharma Korea, Inc. | | 2009-08-01 | 2011-10-11 |
| NCT01981954 | Neurogenic Detrusor Overactivity|Pediatric | Drug: Solifenacin succinate | Astellas Pharma Europe B.V.|Astellas Pharma Inc | Phase 3 | 2013-09-01 | 2016-06-02 |
| NCT00507455 | Lower Urinary Tract Symptoms|Bladder Outlet Obstruction | Drug: solifenacin succinate|Drug: tamsulosin hydrochloride|Drug: Placebo to solifenacin|Drug: Placebo to tamsulosin | Astellas Pharma Inc | Phase 2 | 2007-06-01 | 2014-07-14 |
| NCT01565707 | Urinary Bladder, Overactive | Drug: Solifenacin Succinate Suspension|Drug: Placebo|Behavioral: Urotherapy | Astellas Pharma Europe B.V.|Astellas Pharma Inc | Phase 3 | 2012-06-01 | 2016-12-05 |
| NCT01777217 | Over-Active Bladder | Drug: Solifenacin succinate|Drug: Placebo | Advanced Research Network|Astellas Pharma US, Inc. | Phase 4 | 2013-02-01 | 2015-01-08 |
| NCT01833663 | Overactive Bladder|Postmenopausal Disorder|Urination Disorders | Drug: Solifenacin Succinate Tablets|Drug: Estrogen | Peking Union Medical College Hospital|Astellas Pharma China, Inc.|Beijing CAT Science Co., Ltd. | Phase 4 | 2011-10-01 | 2014-03-19 |
| NCT01655069 | Urinary Bladder, Overactive | Drug: Solifenacin succinate | Astellas Pharma Europe B.V.|Astellas Pharma Inc | Phase 3 | 2012-10-01 | 2015-07-23 |
| NCT01406158 | Pharmacokinetics of Solifenacin Succinate|Healthy Volunteers | Drug: Solifenacin Succinate Formulation A|Drug: Solifenacin Succinate Formulation B|Drug: Solifenacin Succinate | Astellas Pharma Inc | Phase 1 | 2011-05-01 | 2011-08-23 |
| NCT01595152 | Urinary Bladder, Overactive | Drug: solifenacin succinate|Drug: fesoterodine | Rambam Health Care Campus | | 2012-05-01 | 2012-05-14 |
| NCT00454896 | Urinary Bladder, Overactive | Drug: VESIcare|Drug: placebo | Astellas Pharma Inc | Phase 3 | 2004-05-01 | 2014-09-17 |
| NCT01565694 | Neurogenic Detrusor Overactivity | Drug: Solifenacin succinate | Astellas Pharma Europe B.V.|Astellas Pharma Inc | Phase 3 | 2012-09-01 | 2016-07-24 |
| NCT01093534 | Detrusor Overactivity|Overactive Bladder | Drug: Placebo|Drug: solifenacin | Astellas Pharma Inc | Phase 4 | 2010-01-01 | 2017-02-15 |
| NCT00337558 | Overactive Bladder|Urinary Incontinence|Urge Incontinence | Drug: Solifenacin succinate|Behavioral: Simplified bladder training | Astellas Pharma Inc|Astellas Pharma Europe B.V. | Phase 4 | 2006-05-01 | 2014-09-17 |
| NCT02010944 | Phase 1|Bioavailability|Healthy Subjects | Drug: solifenacin succinate|Drug: mirabegron|Drug: mirabegron/solifenacin succinate | Astellas Pharma Europe B.V.|Astellas Pharma Inc | Phase 1 | 2012-09-01 | 2013-12-10 |
| NCT00884104 | Overactive Bladder | Drug: Solifenacin | KYU-SUNG LEE|Astellas Pharma Korea, Inc.|Samsung Medical Center | Phase 4 | 2009-03-01 | 2016-01-06 |
